Table 3.
Histologic characteristics of the allograft at 24 months following randomization by treatment group: TAC maintenance vs. SRL conversion
| Study groups | TAC (n=12) | SRL (n=18) | p-value |
|---|---|---|---|
| Transplant glomerulopathy (cg) – n (%) | |||
| cg0 | 11 (91.6) | 16 (88.0) | 0.950 |
| cg1 | 1 (8.3) | 1 (5.5) | |
| cg2 | 0 (0) | 1 (5.5) | |
| cg3 | 0 (0) | 0 (0) | |
| Interstitial fibrosis and tubular atrophy (IF/TA) – n (%) | |||
| None | 2 (16.6) | 3 (16.6) | 0.930 |
| Mild (<25%) | 9 (75.0) | 13 (72.2) | |
| Moderate (26–25%) | 1 (8.0) | 1 (5.0) | |
| Severe (>50%) | 0 (0) | 1 (5.0) | |
| Arteriosclerosis (cv) – n (%) | |||
| cv0 | 6 (50.0) | 8 (44.4) | 0.940 |
| cv1 | 5 (41.6) | 7 (38.8) | |
| cv2 | 1 (8.3) | 3 (16.6) | |
| cv3 | 0 (0) | 0 (0) | |
| Arteriolar Hyalinosis (ah) – n (%) | |||
| ah0 | 8 (66.6) | 10 (55.5) | 0.890 |
| ah1 | 4 (33.3) | 6 (33.3) | |
| ah2 | 0 (0) | 2 (11.0) | |
| ah3 | 0 (0) | 0 (0) | |
| Tubulitis in IF/TA – n (%) | |||
| in atrophic tubules, >t2* | 1 (8.3) | 5 (27.8) | 0.06 |
| in non atrophic tubules, >t2* | 3 (25) | 2 (11.1) | 0.32 |
| Area of CD68+ Cells – n (%) | |||
| None | 3 (25) | 4 (22.2) | 0.86 |
| Mild (<30 cells/HPF) | 4 (33.3) | 5 (27.8) | 0.74 |
| Modest to numerous (> 30–50 cells/HPF) | 4 (33.3) | 10 (55.6) | 0.23 |
HPF, high-power field
*
tubulitis was scored according to the standard Banff classification scheme, tubulitis in the atrophic tubules was assessed in the same manner as for nonatrophic ones.